Autism spectrum disorder. Childhood autism
Conditions
Interventions
Intervention 1: Case group: 33 patients treated with risperidone tablets with a maximum dose of 1.5 mg daily and n-acetylcysteine tablets 600 mg daily. Intervention 2: Control group: 33 patients treat
Sponsors
Medical Science University of Mashhad
Eligibility
Sex/Gender
All
Age
3 Years to 12 Years
Inclusion criteria
Inclusion criteria: Autism spectrum disorder (ASD) patients aging between 3 to 12 Having parental informed consent IQ score greater than 50 based on Wildland Test Receiving risperidone therapy for at least one month Lack of clear organic disease (based on family history and medical records) Clear organic causes include visual and hearing impairment, seizures, trauma cycles, chronic or acute medical disorder, and brain dysfunction. Psychiatric disorders including Toure's syndrome, Fragile X syndrome, schizophrenia, Attension deficit hyperactivity disorder (ADHD) based on structured psychiatric interview conducted by pediatric psychiatrist
Exclusion criteria
Exclusion criteria: If the parents do not cooperate for any reason after entering the study 2- 3- Use of any psychotropic drugs other than risperidone Any unbearable or life-threatening drug side effect or any other illness that requires medication which may interfere with results of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of ASD was evaluated by CARS questionnaire. Timepoint: Baseline, 5 and 10 weeks after baseline. Method of measurement: CARS questionnaires.;Severity, drug response and drug adverse effects was evaluated by CGI questionnaire. Timepoint: Baseline, 5 and 10 weeks after baseline. Method of measurement: CGI questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPakravan Parisa
Mashhad University of Medical Sciences
Outcome results
None listed